Floatz logo

Sargramostim

Clinical Stage III Merkel Cell Carcinoma AJCC v8

Mayo Clinicprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Clinical Stage III Merkel Cell Carcinoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2/3BB
Fludarabine
Sotio Biotech Inc.
Phase 2B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Ifx-Hu2.0
TuHURA Biosciences, Inc.
Phase 2/3B

View all 50 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →